TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells

Selina K. Sutton, Jessica Koach, Owen Tan, Bing Liu, Daniel R. Carter, James S. Wilmott, Benafsha Yosufi, Lauren E. Haydu, Graham J. Mann, John F. Thompson, Georgina V. Long, Tao Liu, Grant McArthur, Xu Dong Zhang, Richard A. Scolyer, Belamy B. Cheung, Glenn M. Marshall

Research output: Contribution to journalArticleResearchpeer-review

Abstract

High basal or induced expression of the tripartite motif protein, TRIM16, leads to reduce cell growth and migration of neuroblastoma and skin squamous cell carcinoma cells. However, the role of TRIM16 in melanoma is currently unknown. TRIM16 protein levels were markedly reduced in human melanoma cell lines, compared with normal human epidermal melanocytes due to both DNA methylation and reduced protein stability. TRIM16 knockdown strongly increased cell migration in normal human epidermal melanocytes, while TRIM16 overexpression reduced cell migration and proliferation of melanoma cells in an interferon beta 1 (IFNβ1)-dependent manner. Chromatin immunoprecipitation assays revealed TRIM16 directly bound the IFNβ1 gene promoter. Low level TRIM16 expression in 91 melanoma patient samples, strongly correlated with lymph node metastasis, and, predicted poor patient prognosis in a separate cohort of 170 melanoma patients with lymph node metastasis. The BRAF inhibitor, vemurafenib, increased TRIM16 protein levels in melanoma cells in vitro, and induced growth arrest in BRAF-mutant melanoma cells in a TRIM16-dependent manner. High levels of TRIM16 in melanoma tissues from patients treated with Vemurafenib correlated with clinical response. Our data, for the first time, demonstrates TRIM16 is a marker of cell migration and metastasis, and a novel treatment target in melanoma.

LanguageEnglish
Pages10127-10139
Number of pages13
JournalOncotarget
Volume5
Issue number20
DOIs
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Fingerprint

Interferon-beta
Melanoma
Cell Movement
Melanocytes
Neoplasm Metastasis
Lymph Nodes
Protein Stability
Chromatin Immunoprecipitation
DNA Methylation
Growth
Neuroblastoma
Squamous Cell Carcinoma
Proteins
Cell Proliferation
Cell Line
Skin

Bibliographical note

Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • BRAF inhibitor
  • Cell migration
  • IFNβ1
  • Melanoma
  • TRIM16

Cite this

Sutton, S. K., Koach, J., Tan, O., Liu, B., Carter, D. R., Wilmott, J. S., ... Marshall, G. M. (2014). TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 5(20), 10127-10139. https://doi.org/10.18632/oncotarget.2466
Sutton, Selina K. ; Koach, Jessica ; Tan, Owen ; Liu, Bing ; Carter, Daniel R. ; Wilmott, James S. ; Yosufi, Benafsha ; Haydu, Lauren E. ; Mann, Graham J. ; Thompson, John F. ; Long, Georgina V. ; Liu, Tao ; McArthur, Grant ; Zhang, Xu Dong ; Scolyer, Richard A. ; Cheung, Belamy B. ; Marshall, Glenn M. / TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. In: Oncotarget. 2014 ; Vol. 5, No. 20. pp. 10127-10139.
@article{909e136770d1434f9f9d3b0899ca8bd1,
title = "TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells",
abstract = "High basal or induced expression of the tripartite motif protein, TRIM16, leads to reduce cell growth and migration of neuroblastoma and skin squamous cell carcinoma cells. However, the role of TRIM16 in melanoma is currently unknown. TRIM16 protein levels were markedly reduced in human melanoma cell lines, compared with normal human epidermal melanocytes due to both DNA methylation and reduced protein stability. TRIM16 knockdown strongly increased cell migration in normal human epidermal melanocytes, while TRIM16 overexpression reduced cell migration and proliferation of melanoma cells in an interferon beta 1 (IFNβ1)-dependent manner. Chromatin immunoprecipitation assays revealed TRIM16 directly bound the IFNβ1 gene promoter. Low level TRIM16 expression in 91 melanoma patient samples, strongly correlated with lymph node metastasis, and, predicted poor patient prognosis in a separate cohort of 170 melanoma patients with lymph node metastasis. The BRAF inhibitor, vemurafenib, increased TRIM16 protein levels in melanoma cells in vitro, and induced growth arrest in BRAF-mutant melanoma cells in a TRIM16-dependent manner. High levels of TRIM16 in melanoma tissues from patients treated with Vemurafenib correlated with clinical response. Our data, for the first time, demonstrates TRIM16 is a marker of cell migration and metastasis, and a novel treatment target in melanoma.",
keywords = "BRAF inhibitor, Cell migration, IFNβ1, Melanoma, TRIM16",
author = "Sutton, {Selina K.} and Jessica Koach and Owen Tan and Bing Liu and Carter, {Daniel R.} and Wilmott, {James S.} and Benafsha Yosufi and Haydu, {Lauren E.} and Mann, {Graham J.} and Thompson, {John F.} and Long, {Georgina V.} and Tao Liu and Grant McArthur and Zhang, {Xu Dong} and Scolyer, {Richard A.} and Cheung, {Belamy B.} and Marshall, {Glenn M.}",
note = "Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2014",
month = "1",
day = "1",
doi = "10.18632/oncotarget.2466",
language = "English",
volume = "5",
pages = "10127--10139",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "20",

}

Sutton, SK, Koach, J, Tan, O, Liu, B, Carter, DR, Wilmott, JS, Yosufi, B, Haydu, LE, Mann, GJ, Thompson, JF, Long, GV, Liu, T, McArthur, G, Zhang, XD, Scolyer, RA, Cheung, BB & Marshall, GM 2014, 'TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells', Oncotarget, vol. 5, no. 20, pp. 10127-10139. https://doi.org/10.18632/oncotarget.2466

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. / Sutton, Selina K.; Koach, Jessica; Tan, Owen; Liu, Bing; Carter, Daniel R.; Wilmott, James S.; Yosufi, Benafsha; Haydu, Lauren E.; Mann, Graham J.; Thompson, John F.; Long, Georgina V.; Liu, Tao; McArthur, Grant; Zhang, Xu Dong; Scolyer, Richard A.; Cheung, Belamy B.; Marshall, Glenn M.

In: Oncotarget, Vol. 5, No. 20, 01.01.2014, p. 10127-10139.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells

AU - Sutton, Selina K.

AU - Koach, Jessica

AU - Tan, Owen

AU - Liu, Bing

AU - Carter, Daniel R.

AU - Wilmott, James S.

AU - Yosufi, Benafsha

AU - Haydu, Lauren E.

AU - Mann, Graham J.

AU - Thompson, John F.

AU - Long, Georgina V.

AU - Liu, Tao

AU - McArthur, Grant

AU - Zhang, Xu Dong

AU - Scolyer, Richard A.

AU - Cheung, Belamy B.

AU - Marshall, Glenn M.

N1 - Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - High basal or induced expression of the tripartite motif protein, TRIM16, leads to reduce cell growth and migration of neuroblastoma and skin squamous cell carcinoma cells. However, the role of TRIM16 in melanoma is currently unknown. TRIM16 protein levels were markedly reduced in human melanoma cell lines, compared with normal human epidermal melanocytes due to both DNA methylation and reduced protein stability. TRIM16 knockdown strongly increased cell migration in normal human epidermal melanocytes, while TRIM16 overexpression reduced cell migration and proliferation of melanoma cells in an interferon beta 1 (IFNβ1)-dependent manner. Chromatin immunoprecipitation assays revealed TRIM16 directly bound the IFNβ1 gene promoter. Low level TRIM16 expression in 91 melanoma patient samples, strongly correlated with lymph node metastasis, and, predicted poor patient prognosis in a separate cohort of 170 melanoma patients with lymph node metastasis. The BRAF inhibitor, vemurafenib, increased TRIM16 protein levels in melanoma cells in vitro, and induced growth arrest in BRAF-mutant melanoma cells in a TRIM16-dependent manner. High levels of TRIM16 in melanoma tissues from patients treated with Vemurafenib correlated with clinical response. Our data, for the first time, demonstrates TRIM16 is a marker of cell migration and metastasis, and a novel treatment target in melanoma.

AB - High basal or induced expression of the tripartite motif protein, TRIM16, leads to reduce cell growth and migration of neuroblastoma and skin squamous cell carcinoma cells. However, the role of TRIM16 in melanoma is currently unknown. TRIM16 protein levels were markedly reduced in human melanoma cell lines, compared with normal human epidermal melanocytes due to both DNA methylation and reduced protein stability. TRIM16 knockdown strongly increased cell migration in normal human epidermal melanocytes, while TRIM16 overexpression reduced cell migration and proliferation of melanoma cells in an interferon beta 1 (IFNβ1)-dependent manner. Chromatin immunoprecipitation assays revealed TRIM16 directly bound the IFNβ1 gene promoter. Low level TRIM16 expression in 91 melanoma patient samples, strongly correlated with lymph node metastasis, and, predicted poor patient prognosis in a separate cohort of 170 melanoma patients with lymph node metastasis. The BRAF inhibitor, vemurafenib, increased TRIM16 protein levels in melanoma cells in vitro, and induced growth arrest in BRAF-mutant melanoma cells in a TRIM16-dependent manner. High levels of TRIM16 in melanoma tissues from patients treated with Vemurafenib correlated with clinical response. Our data, for the first time, demonstrates TRIM16 is a marker of cell migration and metastasis, and a novel treatment target in melanoma.

KW - BRAF inhibitor

KW - Cell migration

KW - IFNβ1

KW - Melanoma

KW - TRIM16

UR - http://www.scopus.com/inward/record.url?scp=84930468254&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2466

DO - 10.18632/oncotarget.2466

M3 - Article

VL - 5

SP - 10127

EP - 10139

JO - Oncotarget

T2 - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -